Eloralintide for Osteoarthritis
(ENLIGHTEN-4 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for adults over 50 with obesity or overweight (BMI of 27 kg/m² or higher) who have osteoarthritis knee pain. Participants should have tried dieting to lose weight unsuccessfully and must not have had significant weight changes in the last 90 days. They should experience morning knee stiffness lasting around 30 minutes and a crackling sensation in the knee.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Eloralintide or placebo subcutaneously for osteoarthritis knee pain and obesity or overweight
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Eloralintide
Trial Overview
The study tests Eloralintide's effectiveness and safety for those with obesity/overweight and osteoarthritis knee pain. It compares Eloralintide against a placebo over approximately 75 weeks, including initial screening, to determine its impact on managing OA symptoms.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive eloralintide SC
Participants will receive eloralintide subcutaneously (SC)
Participants will receive placebo SC
Participants will receive placebo SC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.